Physiomics Plc (LSE:PYC) has had the kind of year that would test a company fifty times its size. In six months the drug-modelling consultancy raised Equity at a steep discount, saw its entire board voted out by a Shareholder revolt, lost its chief executive to a phased exit and installed new Leadership promising "a path towards breakeven". Yet through the upheaval the Business kept winning work: contracts announced in May and July 2026 alone were worth more than £545,000 combined, against full-year Revenue of just £784,005 in FY25.
With the new board's first full-year results due within weeks, the question for investors in this £2.3m market-cap company is whether sharper commercial focus can turn a growing order book into a business that stops burning cash.
New board, new contracts: the 8 July 2026 award and what followed
The most recent material announcement came on 8 July 2026, when Physiomics disclosed new contracts with a combined estimated value above £200,000. Two were follow-on extensions within its young Biometrics service line, from clinical-stage biotechs in immunology and infectious disease; the third was a modelling and simulation contract with a Boston-based developer of cancer immunotherapies. Jesse Thissen, promoted to Chief Operating Officer on 1 July 2026, said the awards "reflect the continued progress of our Biometrics service line alongside our established Modelling & Simulation capabilities".
That caps a run of wins: on 27 May 2026 the company reported contracts worth more than £345,000, including from a Nasdaq-listed biotech, with revenue expected to flow through to the end of 2027.
The context is what makes these awards significant. On 29 April 2026 a general meeting requisitioned by shareholder Michael Whitlow removed chairman Jim Millen, chief executive Dr Peter Sargent and two other directors, with roughly 78% of votes in favour. Nicholas Tulloch became non-executive chairman, Whitlow (holding around 13% of the shares) executive director and Ian Bagnall finance director. A strategy update on 8 May promised "stronger commercial focus, tighter operational discipline and a more dynamic growth strategy", and an operations update on 26 June said the company was building "its largest commercial pipeline in its history". Dr Sargent continues in a reduced capacity until the end of August 2026.
What Physiomics does
Physiomics is a specialist consultancy that applies mathematical modelling to drug development. Its core modelling and simulation service helps pharmaceutical and biotech clients predict how drug candidates will behave in patients, optimise dosing and design clinical trials. The company says it has informed more than 140 commercial projects and modelled over 125 targets and drugs, with clients including Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.
In mid-2025 it launched a Biometrics service line covering biostatistics and clinical data analysis, which secured four contracts in its first half-year. It has also developed personalised dosing software, deployed for research use through the DoseMeRx platform. Revenue is earned project by project, mainly from clinical-stage biotechs in the UK, Europe and the United States, so the order book and pipeline are the key operating metrics.
Financial performance: growth, but losses persist
The latest audited accounts cover the year to 30 June 2025. Revenue rose 44% to £784,005 (FY24: £543,250) and total income climbed 46% to £834,156. The operating loss narrowed 32% to £457,791 (FY24: £670,816) and the loss after tax was £415,254, or 0.17p per share. Cash at 30 June 2025 stood at £461,242 and net Assets at £692,171, with no going-concern uncertainty flagged by the auditor.
Interim results for the six months to 31 December 2025, published on 16 February 2026, showed revenue up 51% to £498,000 (H1 FY25: £329,000). But operating expenses jumped to £855,000 from £603,000, widening the operating loss to £327,000 (H1 FY25: £249,000); Dr Sargent blamed "temporary reliance on external consultants while new internal staff were onboarded". Cash fell to £257,000 at 31 December 2025 after £203,000 was used in operations. The then board guided to FY26 total income around 27% ahead of FY25 and an after-tax loss around 24% lower.
Cash was subsequently bolstered. A placing at 0.3p announced on 10 March 2026 was cancelled and relaunched a week later at 0.4p, raising £490,000 plus up to £110,000 via a Winterflood retail offer. The new board said in May that it saw cash runway "into 2027" and in June that cost savings would exceed the one-off general meeting expenses, though largely in FY27.
What could move the shares next
The first catalyst is the FY26 results for the year to 30 June 2026; last year's Annual Report came out on 29 September. Investors will be watching whether income tracked the roughly 27% growth guided in February, how far exceptional costs from the boardroom battle dented the bottom line, and the closing cash balance.
Beyond that, contract flow remains the lifeblood: the company has pointed to "anticipated near-term commercial activity", and further Biometrics wins would validate the Diversification strategy. Any monetisation of the personalised dosing software would open a new revenue stream, and the new board's decision to take part of its pay in shares, with Options struck at premiums of 15% and 35% to the June 2026 price, ties its rewards to a higher share price.
Risks investors should watch
Physiomics is a genuine micro-cap, valued at roughly £2.3m–2.4m with the shares at about 0.5p and a bid-offer spread of around 15%; Liquidity is thin. The company remains loss-making and has relied on discounted equity issues; the March 2026 placing was struck at a 14% discount to a share price that had touched a 52-week low of 0.26p in December 2025. Cash of £257,000 at the end of 2025 was modest against a half-year operating cash outflow of £203,000, and the "into 2027" runway leaves little Margin if contract wins slip.
Leadership risk is elevated. There is no titled chief executive following Dr Sargent's departure; day-to-day management rests with an executive director whose background is in small-cap investing rather than pharmacology, alongside a newly promoted COO, and Whitlow's 13% stake concentrates influence. Client concentration is a further concern: a handful of biotechs, notably Numab, account for much of the announced work, and biotech funding cycles can delay or cancel projects. The H1 FY26 cost overrun shows how quickly margins deteriorate when delivery capacity lags demand.
Outlook
Physiomics enters its new financial year with what management calls its largest pipeline ever, but also with a long record of losses. The FY26 results will be the first hard evidence of whether the April 2026 boardroom change has improved execution, and the closing cash figure will show how much time the new team has to prove its case. Shareholders should also monitor contract announcements through the autumn, any update on the CEO position and whether the cost savings promised for FY27 materialise. So far the story is one of rising revenue and unresolved losses; it is the second half of that equation the new board must address.






Please wait processing your request...